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Abstract
Background: Albendazole and mebendazole are increasingly deployed for preventive chemotherapy targeting soil-
transmitted helminth (STH) infections. We assessed the efficacy of single oral doses of albendazole (400 mg) and
mebendazole (500 mg) for the treatment of hookworm infection in school-aged children in Lao PDR. Since Opisthorchis
viverrini is co-endemic in our study setting, the effect of the two drugs could also be determined against this liver fluke.
Methodology: We conducted a randomized, open-label, two-arm trial. In total, 200 children infected with hookworm
(determined by quadruplicate Kato-Katz thick smears derived from two stool samples) were randomly assigned to
albendazole (n = 100) and mebendazole (n = 100). Cure rate (CR; percentage of children who became egg-negative after
treatment), and egg reduction rate (ERR; reduction in the geometric mean fecal egg count at treatment follow-up compared
to baseline) at 21–23 days posttreatment were used as primary outcome measures. Adverse events were monitored 3 hours
post treatment.
Principal Findings: Single-dose albendazole and mebendazole resulted in CRs of 36.0% and 17.6% (odds ratio: 0.4; 95%
confidence interval: 0.2–0.8; P= 0.01), and ERRs of 86.7% and 76.3%, respectively. In children co-infected with O. viverrini,
albendazole and mebendazole showed low CRs (33.3% and 24.2%, respectively) and moderate ERRs (82.1% and 78.2%,
respectively).
Conclusions/Significance: Both albendazole and mebendazole showed disappointing CRs against hookworm, but
albendazole cured infection and reduced intensity of infection with a higher efficacy than mebendazole. Single-dose
administrations showed an effect against O. viverrini, and hence it will be interesting to monitor potential ancillary benefits
of a preventive chemotherapy strategy that targets STHs in areas where opisthorchiasis is co-endemic.
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Introduction
Infections with the three common soil-transmitted helminths
(STHs), Ascaris lumbricoides, Trichuris trichiura, and hookworm
(Ancylostoma duodenale and Necator americanus), are a global public-
health concern, particularly in areas where poor sanitation prevails
[1,2]. STH infections are among the most widespread of the
neglected tropical diseases (NTDs) [3]. Indeed, more than a billion
people are currently infected with one or several STH species,
even though growing efforts are underway to control these
parasitic worm infections [4]. In terms of their estimated global
burden, hookworm is the most important among the STHs,
perhaps responsible for more than 20 million disability-adjusted
life years (DALYs) among the estimated 600 million infected
people worldwide [1,5]. Chronic hookworm infection cause
intestinal blood loss and result in poor iron status and iron-
deficiency anemia, particularly in children, and women in
reproductive age [1,6,7]. As a consequence, permanent impair-
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ment, including delayed physical and cognitive development, has
been described [8].
In the absence of a vaccine, the global strategy to control STHs
and other NTDs is to reduce morbidity through repeated large-
scale administration of anthelmintic drugs, a strategy phrased
preventive chemotherapy [9]. At present, the World Health
Organization (WHO) recommends four drugs against STH
infections, of which albendazole and mebendazole are the two
most widely used drugs for preventive chemotherapy [10]. In
2008, in the Western Pacific Region, 33.4 million children were
given anthelmintic drugs [11]. According to the Lao national
scheme for school deworming, there is a treatment round at the
beginning of the first semester (September–December) and in the
second semester (January–April). Mebendazole (single 500 mg oral
dose) is annually distributed to all school-aged children since 2005
[12]. Recent efforts have been made to provide mebendazole also
to preschool-aged children through the Expanded Program on
Immunization (EPI) and alongside vitamin A distribution
campaigns [4,13]. However, the efficacy of mebendazole and
albendazole against STH infections in Lao PDR remains to be
determined, and such locally derived evidence is important to
guide the national treatment policy.
The liver fluke Opisthorchis viverrini is co-endemic in Lao PDR,
and particularly high prevalences have been observed in the
southern provinces [14–17]. Praziquantel is the current drug of
choice against O. viverrini [3]. Previous work has shown that
multiple doses of albendazole also show some effect [18,19].
Hence, in areas where STHs and O. viverrini co-exist and
preventive chemotherapy targeting STHs is under way, it will be
interesting to monitor for potential ancillary benefits of this control
strategy against opisthorchiasis.
The purpose of this study was to assess the efficacy of single-dose
albendazole (400 mg) and single-dose mebendazole (500 mg)
against hookworm infection among school-aged children in Lao
PDR. In addition, the effect on other STHs (i.e., A. lumbricoides and
T. trichiura) and O. viverrini in co-infected children was assessed. Our
study complements a recent investigation, done in the People’s
Republic of China that compared single and triple dosing with
albendazole and mebendazole against the three common STHs
[20].
Methods
Ethics Statement
The research protocol (see Protocol S1) was approved by the
Ethics Committee of Basel, Switzerland (EKBB; reference
no. 146/08) and the Lao National Ethics Committee for Health
Research (NECHR), Ministry of Health, Vientiane, Lao PDR
(reference no. 170/NECHR). The trial is registered with Current
Controlled Trials (identifier: ISRCTN29126001). Written in-
formed consent was obtained from parents/legal guardians of
eligible children. Participation was voluntary and children could
withdraw from the trial at any time without further obligation.
At completion of the trial, all children of the two primary
schools and participants who were still found positive for
hookworm (or other STHs) were treated with albendazole
(400 mg). O. viverrini-infected children were administered prazi-
quantel according to national guidelines [21].
Study Area and Population
A randomized, open-label trial was carried out between
February and March 2009 in two primary schools (Oudomsouk
and Nongbok Noi) in Batieng district, Champasack province,
southern Lao PDR. Children in the two schools were treated with
mebendazole 5–6 months prior to the start of our study. The
schools are located approximately 15 km southeast of Pakse town,
on the Bolaven plateau at an altitude of approximately 1,000 m
above sea level (geographical coordinates: 105u569530N latitude,
15u149590E longitude). The rainy season lasts from May to mid-
October. A census done in 2007 revealed that 43,651 people lived
in the 95 villages of Batieng district (Dr. Nanthasane Vannavong,
Champasack Provincial Health Department; personal communi-
cation). More than three-quarter of the households (77.5%) lack
appropriate sanitation. Drinking water is primarily obtained from
unprotected boreholes and wells. Most villagers live on subsistence
rice farming and rubber plantations (Dr. Nanthasane Vannavong,
Champasak Provincial Health Department; personal communica-
tion). Infections with STHs and O. viverrini are common in Batieng
district; a recent study revealed infection prevalences above 50%
and above 20%, respectively [22].
Study Design
We designed a randomized, open-label trial comparing
albendazole (single 400 mg dose) and mebendazole (single
500 mg dose) for treatment of hookworm infection. The sample
size was calculated based on results of a meta-analysis on the
efficacy of current anthelmintic drugs against common STH
infections, which reported cure rates (CR; defined as percentage of
helminth-positive individuals who became helminth-egg negative
after treatment) of 75% and 15% for albendazole (400 mg) and
mebendazole (500 mg), respectively against hookworm infection
[10]. In order to account for the large variation (uncertainty) of the
observed efficacy of mebendazole in the individual studies (CRs of
8–91% were found in the six randomized controlled trials), we
more than tripled the mean efficacy of mebendazole (50% instead
of 15%). Assuming superiority of albendazole (1-tailed test) and
taking into account a 90% power, and an alpha error of 5%, we
obtained a sample size of 85 children per treatment group.
Furthermore, we assumed a drop-out rate of 15%, which resulted
Author Summary
Parasitic worms remain a public health problem in
developing countries. Regular deworming with the drugs
albendazole and mebendazole is the current global
control strategy. We assessed the efficacies of a single
tablet of albendazole (400 mg) and mebendazole
(500 mg) against hookworm in children of southern Lao
PDR. From each child, two stool samples were examined
for the presence and number of hookworm eggs. Two
hundred children were found to be infected. They were
randomly assigned to albendazole (n = 100) or mebenda-
zole (n = 100) treatment. Three weeks later, another two
stool samples were analyzed for hookworm eggs. Thirty-
two children who were given albendazole had no
hookworm eggs anymore in their stool, while only 15
children who received mebendazole were found egg-
negative. The total number of hookworm eggs was
reduced by 85.3% in the albendazole and 74.5% in the
mebendazole group. About one third of the children who
were co-infected with the Asian liver fluke Opisthorchis
viverrini were cleared from this infection following
albendazole treatment and about one forth in the
mebendazole group. Concluding, both albendazole and
mebendazole showed disappointingly low cure rates
against hookworm, with albendazole performing some-
what better. The effect of these two drugs against O.
viverrini should be studied in greater detail.
Albendazole and Mebendazole against Hookworm
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in a total sample size of 200 hookworm-positive school-aged
children.
Field and Laboratory Procedures
The teachers of the two primary schools, the children, and the
staff of the National Institute of Public Health, Centre of Malaria,
Parasitology and Entomology, Centre for Laboratory and
Epidemiology, the Provincial Department of Health, the Provin-
cial Hospital, and the Malaria Station of Champassak, and the
village authorities were informed one week in advance on the
study aims and procedures. Potential risks and benefits were
explained to all children and their parents/guardians. An
informed consent form was distributed to all parents/guardians
and signed. Children assented orally.
At baseline screening the consenting children (n= 465) of the
two schools, aged 6–12 years, provided two fresh stool samples
within a period of 3 days. Stool containers were filled by children
and transferred to a laboratory in the early morning (between 8
and 9 am). All collected specimens were worked up on the day of
collection. From each stool sample, duplicate Kato-Katz thick
smears were prepared on microscope slides, using standard
41.7 mg templates [23]. Kato-Katz thick smears were quantita-
tively examined under a light microscope for helminths with a
1006 magnification. Slides were read within 30–45 min after
preparation. A random sample of approximately 10% of the Kato-
Katz thick smears were re-examined by two senior technicians for
quality control purposes. In case of discrepancies (i.e., positive vs.
negative results and egg counts differing by .10%), results were
discussed with the respective technicians, and the slides re-
examined until agreement was reached.
In addition, a questionnaire was administered to each partici-
pating child to obtain sociodemographic data (i.e., sex, age, parent’s
education and occupation, ethnic group, and sanitation infrastruc-
ture), and behavioral data (i.e., wearing shoes, sources of drinking
water, food consumption, and personal hygiene). Hookworm-
positive children (defined by the presence of at least one hookworm
egg in one of the quadruplicate Kato-Katz thick smears examined
per child) were invited for treatment (n= 200).
At enrollment, a clinical examination, which included mea-
surement of weight (using an electronic balance measured to the
nearest 0.1 kg), height (using a measuring tap fixed to the wall and
measured to the nearest cm), and axcillary temperature (using
battery-powered thermometers, measured to the nearest 0.01uC),
anemia assessment (finger prick capillary blood sample) was
conducted, and a medical history taken. Children were excluded if
they had fever, or showed signs of severe malnutrition. Additional
exclusion criteria were the presence of any abnormal medical
condition such as cardiac, vascular, pulmonary, gastrointestinal,
endocrine, neurologic, hematologic (e.g., thalassaemia), rheuma-
tologic, psychiatric, or metabolic disturbances, recent history of
anthelmintic treatment (e.g., albendazole, mebendazole, pyrantel
pamoate, levamisole, ivermectin, and praziquantel), attending
other clinical trials during the study, or reported hypersensitivity to
albendazole or mebendazole.
At follow-up, 21–23 days after drug administration, two stool
samples were collected from each child and transferred to a
hospital laboratory within one hour after collection. Each stool
specimen collected at follow-up was subjected to the same
procedures as during the baseline survey. Hence, duplicate
Kato-Katz thick smears were prepared from each stool sample,
examined under a microscope within 30–45 min by experienced
laboratory technicians, and helminth eggs were counted and
recorded for each species separately. We adhered to the same
quality control as during the baseline survey.
Randomization
Children were randomly assigned to a single dose of
albendazole (400 mg) or mebendazole (500 mg), using a block
randomization procedure (six blocks each containing four
treatment allocations), generated by an independent statistician
who was not otherwise involved in the trial. The sequence of
blocks was determined using a random number table. In addition,
schools were decoded by a researcher to assign children either to
albendazole or mebendazole. Eligible children were randomly
assigned and allocated to treatment by an epidemiologist. Children
and drug administrators were not blinded for drug treatment.
Laboratory personnel and clinicians monitoring the adverse events
were blinded throughout the study.
Drugs and Adverse Events
Albendazole (400 mg; AlbendazoleH, South Korea) was ob-
tained from the Ministry of Health, Vientiane, Lao PDR.
Mebendazole (500 mg; VermoxH, Italy) was donated by Johnson
& Johnson Pharmaceuticals, provided through the Ministry of
Health and the Ministry of Education, Vientiane, Lao PDR. At
treatment day, both groups received the drugs under direct
medical supervision on an empty stomach. Children were
monitored for at least 3 hours after drug administration and
asked to report for any drug-related adverse events using a
standard questionnaire administered and graded by study
physicians.
Statistical Analysis
Data were double-entered and cross-checked in EpiData
version 3.1 (EpiData Association; Odense, Denmark). Statistical
analyses were performed with STATA, version 10.1 (Stata Corp.;
College Station, TX, USA). Efficacy was calculated for both
intention-to-treat (ITT) and per-protocol (PP) analyses. ITT
analysis was based on the initial treatment intent. PP analysis
included only those children who had complete data records (i.e.,
quadruplicate Kato-Katz thick smear reading before and after
treatment, and full treatment compliance).
Infections with hookworm, A. lumbricoides, T. trichiura, and O.
viverrini were grouped into light, moderate, and heavy infections,
according to WHO guidelines (for STHs) and cut-offs put forward
by Maleewong and colleagues and WHO (for O. viverrini) [24,25].
Infection intensity classifications are as follows: hookworm, 1–
1,999 eggs per gram of stool (EPG) (light), 2,000–3,999 EPG
(moderate), and $4,000 EPG (heavy); A. lumbricoides, 1–4,999 EPG
(light), 5,000–49,999 EPG (moderate), and $50,000 EPG (heavy);
and T. trichiura and O. viverrini, 1–999 EPG (light), 1,000–9,999
EPG (moderate), and $10,000 EPG (heavy).
Primary outcome measures were CR and egg reduction rate
(ERR), the latter defined as the positive group’s reduction of
geometric mean (GM) fecal egg count at posttreatment, divided by
the GM fecal egg count at pretreatment, multiplied by 100.
Additionally, changes in class of infection intensities were
determined following treatment. Negative binomial regression
was applied to compare ERRs observed between both treatment
groups. A Wilcoxen test was employed for the matched pair’s
analysis. We determined egg reduction rate ratio (ERRR) and
95% confidence interval (CI). Pearson’s x2-test and Fisher’s exact
test, as appropriate, were used to assess the baseline binary
characteristics between the treatment arms. Statistical significance
was estimated using a likelihood ratio test (LRT). P-value below
5% was considered significant.
CONSORT checklist was followed to report on the trial (see
Checklist S1).
Albendazole and Mebendazole against Hookworm
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Results
Study Cohort
Four hundred sixty-five school-aged children were enrolled in the
baseline screening. Two hundred children (43.0%), 130 boys and 70
girls with a parasitologically confirmed hookworm infection, were
randomly assigned to one of the two treatments. Data of these 200
children were included in the ITT analysis. The remaining 265
children were excluded because they had no hookworm eggs in their
stool (n= 235) or provided only a single stool sample (n= 30).
Overall, 171 children (85.5%) had complete baseline data, received
treatment, and completed follow-up examinations, and hence PP
analysis was performed on these children. Twenty-nine children
(14.5%) were lost to follow-up, 18 in the mebendazole and 11 in the
albendazole group (Figure 1). The 171 children with complete data
records were included in the primary analysis. Their parents most
commonly had completed primary school only (77.5% of parents
for the albendazole group and 80.5% for the mebendazole group).
The most common profession of patients’ parents was farming with
49.4% and 62.2% for albendazole and mebendazole treatment
groups, respectively. The two groups were similar in terms of
household assets, source of drinking water and consumption of
cooked foods as well as raw fish (data not shown). More specifically,
the consumption of raw fish was reported by 61.8% and 58.5%,
respectively, and included dishes like ‘‘Pa Dek’’ (fermented fish
sauce), ‘‘Lap Pa’’, and ‘‘Koy Pa’’ (raw, fish-based dishes).
Baseline Characteristics
At baseline, characteristics of the two treatment groups were
similar (Table 1), including age (albendazole recipients: mean
(standard deviation, SD) age 8.4 (2.1) years; mebendazole
recipients: 8.7 (2.1) years), weight (mean (SD) 23.8 (5.8) kg and
25.0 (5.9) kg, respectively), height (mean (SD) 123.8 (11.0) cm and
126.9 (11.0) cm, respectively), and hemoglobin (Hb) concentra-
tion (mean (SD) 11.8 (1.1) mg/dl and 11.9 (1.3) mg/dl,
respectively). In both treatment groups, most children were
diagnosed with a light hookworm infection (82.0%), whereas the
remaining children had moderate or heavy infection intensities.
The hookworm GM fecal egg counts in the mebendazole and
albendazole groups were 707.0 and 859.1 EPG, respectively
(Table 2).
The overall infection rates of A. lumbricoides, O. viverrini and T.
trichiura were 34.0%, 48% and 45.0%, respectively. O. viverrini GM
fecal egg counts were 84.9 EPG (albendazole) and 120.8 EPG
(mebendazole) (Table 3).
Albendazole and Mebendazole Efficacy against
Hookworm
In the ITT analysis, the CRs of albendazole and mebendazole
against hookworm infection were 32.0% and 15.0%, respective-
ly. Overall, 124 children (73%) remained hookworm-egg
positive; 68 receiving albendazole and 85 in the mebendazole
treatment group. Similar results were obtained with the PP
analysis (Table 2). A statistically significant difference was
observed when comparing the observed CRs using albendazole
vs. mebendazole (OR= 0.4; 95% CI 0.2–0.8; P= 0.01). The
hookworm GM fecal egg counts obtained at follow-up were 63.0
EPG in albendazole recipients and 147.3 EPG in mebendazole
recipients (ITT analysis 96.5 EPG and 210 EPG, respectively).
The respective ERRs for albendazole and mebendazole were
Figure 1. Flow chart detailing the study participation and compliance. Children who completed two stool samples were included in the final
analysis for assessing the efficacy of single-dose albendazole (400 mg) and single-dose mebendazole (500 mg) treatment against hookworm and
concomitant helminth infections in Bachieng district, Champasack province, southern Lao PDR in February/March 2009.
doi:10.1371/journal.pntd.0001417.g001
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86.7% and 76.3% (ERRR 1.0; 95%CI 0.7–1.6; P=0.90. In
children with moderate infection intensities (2,000–3,999 EPG),
the effect of albendazole and mebendazole was significantly
different (P=0.04).
Effect of Albendazole and Mebendazole against A.
lumbricoides, T. trichiura, and O. viverrini
Table 3 shows the effect of albendazole and mebendazole
against A. lumbricoides, T. trichiura, and O. viverrini. At baseline, GM
infection intensities of A. lumbricoides were 1,567 EPG in
albendazole recipients and 1,584 EPG in mebendazole recipients.
Both albendazole and mebendazole treatments achieved high
CRs above 90% and resulted in almost complete egg elimination.
The CRs of albendazole and mebendazole obtained against T.
trichiura were 33.3% and 27.9%, respectively. The respective
ERRs were 67.0% and 66.0%. No statistically significant
difference was observed for CR and ERR between the two
treatments (OR=0.8; 95% CI 0.3–1.9; P=0.58 and
ERRR=0.7; 95% CI 0.3–1.2, P=0.22). Finally, CRs against
O. viverrini achieved with albendazole and mebendazole were
33.3% and 24.2%, respectively (OR= 0.7; 95% CI 0.3–1.9;
P=0.62). The respective ERRs were 82.1% and 78.2%
(ERRR=0.8; 95% CI 0.2–3.9, P=0.78).
Adverse Events
Monitoring of children within 3 hours after drug administration
revealed no drug-related adverse events, neither in the albendazole
nor in the mebendazole group. Hence, both treatments were well
tolerated.
Discussion
This current head-to-head comparison of single-dose albenda-
zole vs. mebendazole against hookworm infection in Lao school-
aged children – to our knowledge the first comparative trial in this
Southeast Asian country – shows sobering results. Indeed, the
standard single oral doses of albendazole (400 mg) and mebenda-
zole (500 mg) that are recommended for preventive chemotherapy
targeting STHs [8,9] resulted in low CRs against hookworm
infection (36.0% and 17.6%, respectively). The respective ERRs
were moderate, (86.7% and 76.3%).
A sizeable number of children were co-infected with A.
lumbricoides, T. trichiura, and O. viverrini, which allowed us to
determine the effect of albendazole and mebendazole against these
helminth species. With regard to A. lumbricoides, high efficacy of
both drugs was confirmed against this helminth species [3,10].
Our study also confirms the previously reported low efficacy of
both drugs against T. trichiura [3,10,26].
While the results obtained with mebendazole against hook-
worm and the efficacy observed with both drugs against A.
lumbricoides and T. trichiura are in line with previous studies
[20,27,28] and in agreement with overall CRs estimated through
a meta-analysis [10], the low CR (36.0%) achieved with
albendazole in the treatment of hookworm infection is somewhat
surprising. Indeed, in the aforementioned meta-analysis, ran-
domized controlled trials of single-dose albendazole (400 mg)
revealed an overall CR against hookworm of 75% [10]. The
reasons for the considerably lower efficacy of albendazole
observed in our study are unclear. Quality control of drug
samples performed in our laboratories revealed that disintegra-
tion, dissolution, and concentration of the albendazole tablets
used in our trial were comparable to ZentelH (data not shown).
The hookworm species (and strains) endemic in southern Lao
PDR might be an explanation. However, there is a paucity of
information on which hookworm species is predominant in
Southeast Asia. Indeed, in our study setting the infection rates of
the two hookworm species, A. duodenale and N. americanus, are not
known. Furthermore, recent studies documented that in South-
east Asia humans are at risk of acquiring Ancylostoma ceylanicum,
which is endemic in dogs and cats of the region and its
importance in humans might be underestimated [29,30]. Hence,
further analysis on the circulating parasite species is required to
elucidate this issue. In addition, day-to-day variability in
hookworm egg counts from individuals is a well described
Table 1. Baseline characteristics of 171 hookworm-infected
school children, Bachieng district, Champasak province, Lao
PDR, in February/March 2009.
Albendazole
(n=89)
Mebendazole
(n = 82)
Boys/girls 56/33 49/33
Mean (SD) age, years 9.0 (2.1) 9.0 (2.1)
Mean (SD) weight, kg 24.0 (6.0) 25.2 (6.0)
Mean (SD) height, cm 124.1 (11.0) 127.0 (11.0)
Mean (SD) hemoglobin, mg/dl 11.9 (1.1) 12.4 (1.3)
Anemia (,11.5 mg/dl), n, (%)a 23 (57.5) 17 (42.5)
Latrine facility present, n, (%) 5 (5.6) 1 (1.2)
Parasitic infections
Hookworm infectionb
Light (1–1,999 EPG) 72 (80.9) 67 (81.7)
Moderate (2,000–3,999 EPG) 9 (10.1) 7 (8.6)
Heavy ($4,000 EPG) 8 (9.0) 8 (9.7)
Co-infection with
Ascaris lumbricoidesb
Negative 61 (68.5) 53 (64.6)
Light (1–4,999 EPG) 18 (20.2) 18 (22.0)
Moderate (5,000–49,999 EPG) 7 (7.9) 8 (9.8)
Heavy ($50,000 EPG) 3 (3.4) 3 (3.7)
Trichuris trichiurab
Negative 51 (57.3) 39 (47.6)
Light (1–999 EPG) 38 (42.7) 43 (52.4)
Moderate (1,000–9,999 EPG) 4 (4.5) 0
Heavy ($10,000 EPG) 0 0
Taenia spp.
Negative 78 (87.6) 79 (96.3)
Positive 11 (12.4) 3 (3.7)
Opisthorchis viverrinic
Negative 44 (49.4) 50 (61.0)
Light (1–999 EPG) 41 (46.1) 25 (30.5)
Moderate (1,000–9,999 EPG) 4 (4.5) 7 (8.5)
Heavy ($10,000 EPG 0 0
aAccording to guidelines put forth by WHO regarding definition of anemia [42].
bAccording to guidelines put forth by WHO [25], based on Kato-Katz thick smear
examination.
cAccording to Maleewong and colleagues [24], based on Kato-Katz thick smear
examination.
Data are no; (%) of subject, otherwise indicated (95% confidence interval); EPG,
eggs per gram of stool; GM, geometric mean.
doi:10.1371/journal.pntd.0001417.t001
Albendazole and Mebendazole against Hookworm
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phenomenon [31]. Finally, the study’s sample size is rather small
and therefore a few incidental effects such as failure of some
children to swallow the tablet correctly, might have contributed
to low efficacy of albendazole for the treatment of hookworm
infection. To sum up, differences in strain and species
susceptibilities, host factors, and co-infections with other
Table 2. Hookworm infection at baseline and follow-up and cure rate of albendazole and mebendazole (per-protocol analysis).
Pretreatment Posttreatment
Albendazole
(n=89)
Mebendazole
(n=82)
Albendazole
(n=89)
Mebendazole
(n = 82)
No. of hookworm-infected patients 89 (100) 82 (100) 57 (64.0) 67 (81.7)
No. of children cured (cure rate, %) n.a. n.a. 32 (36.0) 15 (17.6)a
Light infection (1–1,999 EPG) 72 (80.9) 67 (48.2) 55 (61.8) 59 (72)
No. of children cured (cure rate, %) n.a. n.a. 17 (19.1) 8 (9.8)b
Moderate infection (2,000–3,999 EPG) 9 (18.0) 7 (46.7) 2 (2.2) 6 (7.3)
No. of children cured (cure rate, %) n.a. n.a. 7 (7.9) 1 (1.2)c
Heavy infection ($4,000 EPG) 8 (1.1) 8 (1.1) 0 (0) 2 (2.4)
No. of children cured (cure rate, %) n.a. n.a. 8 (9) 6 (7.3)d
GM fecal egg count (range), EPG 859.1 (699.0–1,057.0) 707.0 (559.0–894.3) 63.0 (34.0–116.0) 147.3 (90.0–242.0)
Egg reduction rate, % n.a. n.a. 86.7 76.3e
aOR 0.4 [95% CI (0.2–0.8; P = 0.01)] comparison of treatment outcomes between mebendazole vs. albendazole;
bP= 0.13;
cP= 0.04;
dP= 0.46;
eERRR 1.0 [95% CI (0.7–1.6; P = 0.90)] comparison of treatment outcomes between mebendazole vs. albendazole.
Note. Data are number; (%) of children, unless otherwise indicated (95% confident interval); GM, geometric mean; EPG, eggs per gram of stool; ERRR egg reduction rate ratio;
OR odds ratio; n.a. not applicable.
doi:10.1371/journal.pntd.0001417.t002
Table 3. Infection rate and cure rate of albendazole and mebendazole for hookworm co-infections.
Pretreatment Posttreatment
Albendazole Mebendazole Albendazole Mebendazole
Parasitic infection
A. lumbricoides (n = 58) (n= 28) (n= 30) (n= 28) (n = 30)
No. of A. lumbricoides-infected children 28 (100) 30 (100) 2 (7.1) 2 (6.7)
No. of patients cured (cure rate, %) n.a. n.a. 26 (92.9)a 28 (93.3)a
GM fecal egg count (range), EPG 1,567.0 (553.0–4,444.0) 1,584.0 (528.0–4,751.0) 0 0
ERR, % n.a. n.a. 100b 100b
T. trichiura (n = 82) (n= 39) (n= 43) (n= 39) (n = 43)
No. of T. trichuris-infected children 39 (100) 43 (100) 26 (66.7) 31 (72.1)
No. of patients cured (cure rate, %) n.a. n.a. 13 (33.3) 12 (27.9)c
GM fecal egg count (range), EPG 94.1 (48.3–184.0) 65.2 (39.3–108.3) 75.0 (42.2–133.2) 48.0 (25.0–93.0)
ERR n.a. n.a. 67.0d 66.0d
O. viverrini (n = 77) (n= 45) (n= 32) (n= 45) (n = 32)
No. of O. viverrini-infected children 45 (100) 32 (100) 30 (66.7) 25 (75.8)
No. of patients cured (cure rate, %) n.a. n.a. 15 (33.3)e 8 (24.2)e
GM fecal egg count (range), EPG 84.9 (41.8–184.0) 120.8 (48.9–297.9) 73.0 (34.3–155.7) 114.4 (48.9–267.3)
ERR, % n.a. n.a. 82.1f 78.2f
aOR 0.8 [95% CI (0.2–2.6; P = 0.71) comparison of treatment outcomes between mebendazole vs. albendazole.
bERRR n.a.
cOR 0.8 [95% CI (0.3–1.9; P = 0.58)] comparison of treatment outcomes between mebendazole vs. albendazole.
dERRR 0.7 [95% CI (0.3–1.2; P = 0.22)] comparison of treatment outcomes between mebendazole vs. albendazole.
eOR 0.7 [95% CI (0.3–1.9; P = 0.62)] comparison of treatment outcomes between mebendazole vs. albendazole.
fERRR 0.8 [95% CI (0.2–3.9; P = 0.78)] comparison of treatment outcomes between mebendazole vs. albendazole.
Note. Data are number; (%) of children, unless otherwise indicated (95% confident interval); GM, geometric mean; EPG, eggs per gram of stool; ERRR, egg reduction rate ratio;
OR odds ratio; n.a. not applicable.
doi:10.1371/journal.pntd.0001417.t003
Albendazole and Mebendazole against Hookworm
www.plosntds.org 6 January 2012 | Volume 6 | Issue 1 | e1417
helminths are factors that might all play a role in explaining
treatment failures [28,32].
Nevertheless, we cannot rule out that albendazole resistance is
developing in our study setting. To date, nematode resistance in
humans has not been reported. On the other hand, drug resistance
is a major problem in veterinary public health [33,34]. The
development of broad spectrum anthelmintic resistance, in
particular resistance of nematodes to benzimidazoles, has been
recognized in ruminants for decades [34,35]. Extensive studies on
the underlying mechanisms of drug resistance have been carried
out [36]. Further investigations on failure of the drugs to
completely cure the patients are necessary in our study setting to
substantiate this suspicion.
It is interesting to note that the two drugs employed, even at
single oral doses, showed some effect against O. viverrini. Although
CRs were low (24.2–33.3%), the moderate ERRs of 78.2–82.1%
are encouraging. At present, praziquantel is the drug of choice
against opisthorchiasis [3,18]. Studies carried out in the 1980s in
O. viverrini-infected hamsters and patients infected with O. viverrini
documented opisthorchicidal properties of albendazole and
mebendazole [19,37]. However, long treatment courses of up
to 7 days were recommended in view of these initial laboratory
and clinical findings. Experiences with long treatment courses
have been reported from a hospital-based randomized trial;
albendazole given at dosages of 400 mg twice daily for 3 and 7
days resulted in CRs of 40% and 63%, respectively, and
corresponding ERRs of 92% [19]. Furthermore, mebendazole
in dosages of 30 mg/kg daily for 3 or 4 weeks resulted in CRs of
94% against O. viverrini. Long treatment courses compromise
compliance, increase costs and are not feasible for large-scale
community-based control, which might explain that albendazole
and mebendazole were not further promoted for O. viverrini
treatment [37].
It should be noted that in our study Kato-Katz thick smears
served as method for helminth diagnosis. However, this diagnostic
approach does not allow differentiating the eggs of O. viverrini from
minute intestinal flukes [38,39]. In addition, since the emphasis of
our research was on hookworm, the efficacy of albendazole and
mebendazole against other STHs and O. viverrini could not be
compared with the appropriate sample sizes. Finally, mostly light
O. viverrini infections were present in our study and the sample of O.
viverrini-infected patients was not representative of the overall
community as hookworm infection was the leading selection
criterion. Hence, additional clinical investigations are warranted to
assess the opisthorchicidal properties of albendazole and meben-
dazole in comparison to praziquantel. Moreover, the anthelmintic
drug tribendimidine [40] showed high CR and ERR against O.
viverrini in a recent, open-label exploratory trial carried out in Lao
PDR [41]. It would therefore be interesting to conduct a four-arm
study, comparing praziquantel (treatment of choice) with triben-
dimidine, albendazole, and mebendazole.
In conclusion, we have assessed the efficacy of standard single-
dose regimens of albendazole and mebendazole against hookworm
infection in school-aged children from Lao PDR and provide
further evidence of the effects these two drugs have against other
helminth species concurrently harbored in the human host. Both
drugs showed a similar profile, with low efficacy against hookworm
and, additionally, low efficacy against T. trichiura, and high efficacy
against A. lumbricoides. The low efficacy of single-dose of
albendazole against hookworm should be followed-up closely
and further investigated as this drug is widely used for preventive
chemotherapy against STHs and in combination with ivermectin
in the current global effort to eliminate lymphatic filariasis. The
effects of the two drugs against O. viverrini warrant further
investigations, in comparison with the current drug of choice
praziquantel as well as tribendimidine.
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